Medicare Drug Payment Demonstration May Advance In 2023 Under Executive Order
Demonstration would ‘build on’ Medicare price controls established by the Inflation Reduction Act, White House says.
You may also be interested in...
All Carrots, No Sticks: House Republican Drug Shortage Plan Ups Reimbursement But Lacks Supply, Quality Commitments
New Republican House Energy and Commerce shortage plan is seen as reasonable starting point, though in need of much strength to address root causes of supply troubles. Most changes apply to generic drugs, but a few could impact brands.
The Center for Medicare and Medicaid Innovation also will develop demonstrations focused on payment arrangements for cell and gene therapy in Medicaid and promoting generic drugs in Medicare Part D.
Many of the same factors that held down large M&A transactions in 2021 carried over to 2022, which saw eight buyouts valued at $2bn+, headlined by Amgen’s $27.8bn purchase of Horizon.